WHITEPAPER: HAS COVID-19 REVOLUTIONIZED THE CLINICAL TRIALS SUPPLY CHAIN?
How has the pandemic caused industry to rise to the patient-centric challenge in the last two years?
Covid-19 brought unprecedented levels of disruption to the global clinical trials supply chain, with many studies paused or postponed, while others ran at incredible speed in the race to develop a vaccine.
Patient recruitment and management also presented major challenges to industry during the pandemic, underlining the need for companies to take an increasingly patient-centric approach.
In this whitepaper, we will explain how the pandemic impacted the clinical trials industry from a clinical labeling management perspective. We will also explore how companies can overcome some of the barriers to setting up and running clinical trials and streamline their operations to enable packs to be dispatched faster, while ensuring regulatory compliance.